＜2934＞ J Frontier 1485 -101

whereabouts. After the transaction ended on the 2nd, the full-year earnings forecast for the fiscal year ending 24/5 was withdrawn, and it was announced that it was undecided, and sales that were disgusting about this have come out. Investigations by the Special Investigation Committee are ongoing, and the specific amount of impact on financial results for the fiscal year ending 24/5 has not been determined, and the reason is that it is currently difficult to forecast full-year results for the fiscal year ending 24/5. At the same time, it was announced that the deadline for submitting securities reports for the fiscal year ending 24/5 was extended from 9/2 to 11/29, and it was approved.

＜5578＞ AR Advanced 1429 +18

fight. Research on AI prediction and knowledge sharing systems for general anesthesia patient states is being carried out jointly with the Yokohama City University Medical School Department of Anesthesiology Science and the medical corporation Yokohama Future Health Care System Totsuka Kyoritsu No. 2 Hospital, and it was announced that they have applied for a patent related to the same matter under the joint name of the 3 parties as of 7/10, and it is viewed as good news. In the future, it is planned to conduct demonstration tests to verify the practicality of the system and work towards launch. Also, it was announced that the novelty of the study was registered as an abstract at the British Society of Anesthesiologists academic conference, which is prestigious in Europe, and was adopted for presentation.

＜2586＞ Frutta 97 -29

A sharp decline. From the 3rd, the Tokyo Stock Exchange announced that the contract deposit rate relating to new sales and purchases of the company's shares will be 90% or more (of which 60% or more in cash), and they are being sold disgusted by the strengthening of margin trading regulations. Also, Japan Securities Finance also says that the loan guarantee ratio relating to the loan transaction self transaction amount and the liquidation agency loan transaction self transaction amount for each non-liquidation participant will be 90% (of which 60% is cash collateral).

＜4167＞ Kokopelli 494 +30

Continued growth. After the transaction ended on the 2nd, the group company Key Point announced that it had begun developing services to support DX of regional financial institutions, and it was viewed as good news. Utilizing Kokopelli's network of financial institutions, we have started developing in-house services such as secure file sharing and email management to support improved work efficiency. Through services, information leaks and oversights of important information are prevented in the financial industry with strict security requirements, and by supporting optimization of resource allocation, it contributes to improving productivity and operational efficiency of financial institutions.

＜4579＞ LaQuoria Drug Discovery 630 +14

backlash. Mexico Carnot, which is a sublicensable company, announced that it has obtained sales approval in Colombia for the gastric acid secretion suppressor tegoprazan, which was licensed through HK Innoen in Korea. Tegoprazan is a gastric acid secretion inhibitor with a new mechanism of action called a potassium ion competitive acid blocker (P-CAB) created by the company. P-CAB is a new-generation therapeutic agent that suppresses gastric acid secretion more quickly and continuously than proton pump inhibitors (PPI), which are first-line drugs for gastroesophageal reflux disease treatment.

＜4572＞ Carna Bio 460 +44

Significant continued growth. Regarding the next-generation BTK inhibitor AS-1763, which is being developed as a target disease for blood cancer, it was announced that it has been decided to start a phase 1b test/dose expansion part, and it has been well received. Since it has been possible to confirm the high safety and tolerability of AS-1763 as well as sufficient blood drug concentration and high overall response efficiency that can be expected to have a therapeutic effect in the middle of the dose escalation part up to now, it was decided to move to the dose expansion part without waiting for the start of the maximum dose (600 mg BID) planned in the dose escalation part under the agreement of the doctor responsible for the clinical trial.